Recent Finacing
Recent Raise
Inositec develops small-molecule therapeutics derived from inositol hexaphosphate (IP6) using its Inositune platform to tune chemical and physical properties, initially targeting vascular calcification and C. difficile infections.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors